Your browser doesn't support javascript.
loading
Immunoregulatory functions of VISTA.
Nowak, Elizabeth C; Lines, J Louise; Varn, Frederick S; Deng, Jie; Sarde, Aurelien; Mabaera, Rodwell; Kuta, Anna; Le Mercier, Isabelle; Cheng, Chao; Noelle, Randolph J.
Affiliation
  • Nowak EC; Department of Microbiology and Immunology, Norris Cotton Cancer Center Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
  • Lines JL; Department of Microbiology and Immunology, Norris Cotton Cancer Center Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
  • Varn FS; Department of Biomedical Data Science and Department of Molecular and Systems Biology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
  • Deng J; Department of Microbiology and Immunology, Norris Cotton Cancer Center Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
  • Sarde A; Department of Microbiology and Immunology, Norris Cotton Cancer Center Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
  • Mabaera R; Department of Microbiology and Immunology, Norris Cotton Cancer Center Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
  • Kuta A; Department of Microbiology and Immunology, Norris Cotton Cancer Center Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
  • Le Mercier I; ImmuNext, Inc., Lebanon, NH, USA.
  • Cheng C; Department of Biomedical Data Science and Department of Molecular and Systems Biology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
  • Noelle RJ; Department of Microbiology and Immunology, Norris Cotton Cancer Center Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
Immunol Rev ; 276(1): 66-79, 2017 03.
Article in En | MEDLINE | ID: mdl-28258694
ABSTRACT
Utilization of negative checkpoint regulators (NCRs) for cancer immunotherapy has garnered significant interest with the completion of clinical trials demonstrating efficacy. While the results of monotherapy treatments are compelling, there is increasing emphasis on combination treatments in an effort to increase response rates to treatment. One of the most recently discovered NCRs is VISTA (V-domain Ig-containing Suppressor of T cell Activation). In this review, we describe the functions of this molecule in the context of cancer immunotherapy. We also discuss factors that may influence the use of anti-VISTA antibody in combination therapy and how genomic analysis may assist in providing indications for treatment.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: B7 Antigens / Immunotherapy / Antibodies, Monoclonal / Neoplasms Limits: Animals / Humans Language: En Journal: Immunol Rev Year: 2017 Document type: Article Affiliation country: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: B7 Antigens / Immunotherapy / Antibodies, Monoclonal / Neoplasms Limits: Animals / Humans Language: En Journal: Immunol Rev Year: 2017 Document type: Article Affiliation country: United States